» Articles » PMID: 35183749

Variability of Interferon-γ Release Assays in People at High Risk of Tuberculosis Infection or Progression to Tuberculosis Disease Living in the United States

Overview
Publisher Elsevier
Date 2022 Feb 20
PMID 35183749
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Interferon-γ release assays, including T-SPOT.TB (TSPOT) and QuantiFERON Gold In-Tube (QFT), are important diagnostic tools for tuberculosis infection, but little work has been done to study the performance of these tests in populations prioritized for tuberculosis testing in the United States, especially those other than health care personnel.

Methods: Participants were enrolled as part of a large, prospective cohort of people at high risk of tuberculosis infection or progression to tuberculosis disease. All participants were administered a tuberculin skin test, TSPOT, and QFT test. A subset of participants had their QFT (n = 919) and TSPOT (n = 885) tests repeated when they returned to get their tuberculin skin test read 2 to 3 days later (repeat study). A total of 531 participants had a TSPOT performed twice on the same sample taken at the same time (split study).

Results: The QFT repeat test interpretations were discordant (one test positive and the other negative) for 6.4% of participants (59 of 919), and the TSPOT tests were discordant for 60 of 885 participants in the repeat study (6.8%) and 41 of 531 participants in the split study (7.7%). There was a high degree of variability in the quantitative test results for both QFT and TSPOT, and discordance was not associated with both test results being near the established cut-offs. Furthermore, the proportion of discordance was similar when comparing participants in both the TSPOT repeat and TSPOT split studies.

Discussion: Both QFT and TSPOT were 6% to 8% discordant. The results should be interpreted with caution, particularly when seeing a conversion or reversion in serial testing.

Citing Articles

Bacillus Calmette-Guérin (BCG) Vaccine in America and Overseas: A Narrative Review.

Kaye A, Giles T, OBrien E, Zajac J, Upshaw W, Jenks K Cureus. 2024; 16(11):e73602.

PMID: 39677124 PMC: 11640066. DOI: 10.7759/cureus.73602.


Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.

Chin K, Anibarro L, Sarmiento M, Acosta A Trop Med Infect Dis. 2023; 8(2).

PMID: 36828505 PMC: 9960903. DOI: 10.3390/tropicalmed8020089.

References
1.
Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

2.
Collins J, Stout J, Ayers T, Hill A, Katz D, Ho C . Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth-United States, 2012-2017. Clin Infect Dis. 2020; 73(9):e3468-e3475. PMC: 8563169. DOI: 10.1093/cid/ciaa1662. View

3.
Leyten E, Prins C, Bossink A, Thijsen S, Ottenhoff T, van Dissel J . Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay. Eur Respir J. 2007; 29(6):1212-6. DOI: 10.1183/09031936.00117506. View

4.
Stout J, Belknap R, Wu Y, Ho C . Paradox of serial interferon-gamma release assays: variability width more important than specificity size. Int J Tuberc Lung Dis. 2018; 22(5):518-523. PMC: 9132738. DOI: 10.5588/ijtld.17.0650. View

5.
Lewinsohn D, Leonard M, LoBue P, Cohn D, Daley C, Desmond E . Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017; 64(2):111-115. PMC: 5504475. DOI: 10.1093/cid/ciw778. View